SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Rossari Biotech surges on getting nod to acquire Tristar Intermediates

19 Jul 2021 Evaluate

Rossari Biotech is currently trading at Rs. 1232.40, up by 64.05 points or 5.48% from its previous closing of Rs. 1168.35 on the BSE.

The scrip opened at Rs. 1178.80 and has touched a high and low of Rs. 1248.00 and Rs. 1178.80 respectively. So far 30945 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1347.60 on 10-May-2021 and a 52 week low of Rs. 663.55 on 23-Jul-2020.

Last one week high and low of the scrip stood at Rs. 1248.00 and Rs. 1158.30 respectively. The current market cap of the company is Rs. 6419.08 crore.

The promoters holding in the company stood at 68.70%, while Institutions and Non-Institutions held 21.42% and 9.88% respectively.

Rossari Biotech’s board has approved the acquisition of Tristar Intermediates at an enterprise value of Rs 120 crore. A move which will help Rossari Biotech expand its product portfolio, primarily in the personal care segment.

As per the agreement and subject to customary closing conditions, Rossari will be acquiring 100 percent equity share capital of Tristar Intermediates. 76 percent of the equity share capital will be acquired upon closure of the transaction, and the balance 24 percent over the next three years.

Rossari Biotech is a specialty chemicals manufacturing firm with focus on home and personal care, performance chemicals, textile specialty chemicals and animal health and nutrition products. Apart from India, it has operations in 17 countries including Vietnam, Bangladesh and Mauritius.

Rossari Biotech Share Price

480.15 1.40 (0.29%)
04-May-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3651.95
Tata Chemicals 804.85
SRF 2551.40
Pidilite Inds. 1364.45
Deepak Nitrite 1751.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×